PCOS Is Now PMOS: What the Name Change Means for Your Care
PCOS Is Now PMOS: What the Name Change Means for Your Care
As of today, the condition that 1 in 8 women globally has been diagnosed with for decades has a new name. PCOS is now PMOS — Polyendocrine Metabolic Ovarian Syndrome.
This isn't a rebrand. It's a 14-year effort by the Endocrine Society, the International Androgen Excess and PCOS Society, Verity (PCOS UK), Monash University, and 50+ other patient and professional organizations to fix a name that has been actively harmful for decades. The change was published in The Lancet today and is the most significant shift in how this condition is framed since it was first described.
Notably, one of the lead authors on the Lancet paper is Dr. Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz. The science driving this change has roots right here in Colorado.
So what does it actually mean — for patients already diagnosed, for women still trying to figure out what's going on, and for how care should look going forward? Here's the plain-English version.
Why "PCOS" Was Wrong All Along
The original name, polycystic ovary syndrome, focused on what doctors thought they were seeing on ultrasound: cysts on the ovaries. The problem is that's not really what the condition is, and in many cases those aren't even cysts in the medical sense.
A companion paper in The Lancet, published alongside the name change, confirmed something clinicians have suspected for years: women with this condition do not have an increase in abnormal ovarian cysts. The follicles seen on ultrasound are part of normal ovarian function caught at a particular point in the cycle, not pathological cysts.
The old name caused real damage:
- Patients without visible cysts on ultrasound were sometimes told they couldn't have "PCOS," delaying diagnosis
- The focus on ovaries obscured the metabolic and hormonal drivers of the condition
- Many providers treated it primarily as a reproductive issue rather than the multi-system endocrine disorder it actually is
- Insurance and research funding followed the ovarian framing, which limited the kinds of treatments studied
The Endocrine Society and the multi-organization group behind the change describe the old name as inaccurate, stigmatizing, and a barrier to good care. After 14 years of work — and surveys of over 14,300 patients and clinicians worldwide — the consensus is finally here.
What "Polyendocrine Metabolic Ovarian Syndrome" Actually Means
The new name is longer, but it's also more accurate. Each word matters:
Polyendocrine
"Multiple hormones." This condition isn't about one hormone — it's about how several hormone systems interact dysfunctionally. Insulin, androgens (testosterone), luteinizing hormone, sex hormone-binding globulin, and others are all involved. Treating just one of these in isolation misses the picture.
Metabolic
This is the word that changes the most about how the condition should be treated. Insulin resistance is the engine of PMOS for most women who have it. When the body becomes less responsive to insulin, the pancreas pumps out more — and the resulting high insulin levels signal the ovaries to make more testosterone than they should. That high testosterone is what drives the visible symptoms: irregular cycles, acne, unwanted hair growth, weight gain that won't respond to typical interventions, and difficulty conceiving.
Ovarian
The ovaries are still involved. They're producing abnormal hormone levels and that affects reproduction. But they're downstream of the metabolic and endocrine drivers, not the source of the problem.
Syndrome
A syndrome is a collection of features that often appear together but don't have one single cause or one single treatment. PMOS shows up differently in different women. Some have prominent metabolic symptoms; others have prominent reproductive symptoms; some have both equally. The treatment approach has to be individualized, which the new name implicitly acknowledges.
The Insulin Resistance Story
If there's one thing to take away from this name change, it's the centrality of insulin resistance to most PMOS cases.
Dr. Cree, the UC Anschutz author of the Lancet paper, put it plainly in interviews this week: there's too much insulin in many women with this condition, and that insulin "confuses the ovary to make too much testosterone." High testosterone is what drives most of the visible symptoms women experience.
This matters because it changes the order of operations in treatment. The old PCOS framework often led with hormonal birth control to manage symptoms. That can be a valid choice for some women, but it doesn't address insulin resistance — and in some cases birth control can make insulin resistance slightly worse.
The new framework prioritizes:
- Lifestyle modifications as the foundation — sleep, exercise, dietary changes that reduce blood sugar volatility
- Insulin-sensitizing approaches — metformin remains the most-studied; myo-inositol has solid evidence as a comparable alternative with fewer side effects
- Weight management when relevant — including GLP-1 medications for women whose PMOS is significantly driven by metabolic dysfunction
- Hormonal support layered on top — birth control, androgen blockers, or BHRT in specific cases — but as part of a larger plan rather than the first move
It's not that the older treatments are wrong. It's that they were too often deployed without addressing the underlying insulin problem first.
What This Changes About Treatment
For the women we see in our Centennial and Alamosa clinics, the renaming validates an approach we've been using for years: lab work first, metabolic and hormonal context together, and a treatment plan that addresses the root cause rather than just the visible symptoms.
Here's how the treatment landscape looks under the PMOS framework:
Tier 1: Lifestyle (still #1)
Sleep quality, blood-sugar-stabilizing eating patterns, regular movement, and stress management. These aren't optional — they're foundational. Dr. Cree was direct in her public comments this week: "We're not trying to be judgmental. There is science to back this up." The science is strong, and for many women lifestyle changes alone produce significant improvement.
Tier 2: Insulin sensitizers
Metformin has decades of data and remains the most prescribed pharmacological option. Myo-inositol — typically combined with D-chiro-inositol — has accumulated strong meta-analysis support and is often better tolerated. The choice between them depends on individual factors and how aggressive the metabolic picture is.
Tier 3: GLP-1 medications
This is the part of the conversation that's evolving fastest. GLP-1 receptor agonists — semaglutide, tirzepatide — are not FDA-approved for PMOS. Their approved indications are for type 2 diabetes and chronic weight management. But for women whose PMOS is significantly weight-driven, the off-label use of GLP-1s is growing, and the early data is genuinely promising. Insurance coverage is inconsistent precisely because this isn't a labeled indication. When we use these medications for women whose clinical picture warrants it, we're transparent about the off-label nature and we monitor closely.
Tier 4: Targeted hormonal support
Spironolactone for androgen-driven symptoms (acne, unwanted hair). Hormonal birth control when contraception is also a goal. Bioidentical hormone replacement therapy in perimenopausal women whose PMOS is now interacting with declining estrogen and progesterone. The order matters: address the metabolic engine first, then refine.
What This Means for Women Currently Diagnosed
Your diagnosis didn't change today. If you've been told you have PCOS, you still have the same condition — it just has a new name. You don't need new labs or a new diagnostic workup based on the renaming alone.
What might change is the conversation you have with your provider. Worth asking:
- What does my insulin resistance picture actually look like — and have we measured it directly?
- Is my current treatment plan addressing the metabolic component, or only managing symptoms?
- What lifestyle and pharmacological options haven't been part of my care that should be considered now?
- If I'm on hormonal birth control, what's the long-term plan if I want to come off it or eventually conceive?
The shift the medical community is making isn't about throwing out everything that worked. It's about rebalancing toward a more accurate understanding of the underlying biology — and a more personalized approach to care.
How Defiance Approaches PMOS Care
For the women we work with in our Centennial and Alamosa clinics, our approach already aligns with the new framework. That's not because we predicted the name change — it's because the underlying clinical reality has been clear for a while, and good functional and integrative care has been moving this direction independently.
What that looks like in practice:
- Comprehensive lab work first. Our intake includes a full hormone panel, fasting insulin, HbA1c, lipid panel, and inflammation markers. You can't treat what you haven't measured. This is part of our comprehensive hormone evaluation and is also available through our direct-to-consumer lab testing.
- Lifestyle support that's actually individualized. Not generic "eat better and exercise" — specific guidance based on your labs and your starting point.
- Insulin sensitizers when indicated. Metformin and inositol are both in our toolkit. The right choice depends on the patient.
- GLP-1 medications under close supervision. Our medical weight loss program uses semaglutide and tirzepatide for women whose metabolic picture warrants it, with full transparency about the off-label aspect for PMOS specifically.
- Bioidentical hormone replacement therapy when appropriate — particularly for women whose PMOS is overlapping with perimenopause or whose hormone picture needs targeted support beyond insulin sensitivity.
- Ongoing monitoring through telehealth. PMOS is a long-term condition. We're set up to follow patients over time, not just see them once and let them figure it out.
None of this is novel because we're using the new name. It's how thoughtful, individualized hormonal and metabolic care should have been delivered the whole time.
The Colorado Connection
It's worth noting that Dr. Melanie Cree at the University of Colorado Anschutz Medical Campus was one of the authors on the Lancet paper that made this change happen. Colorado academic medicine — particularly in pediatric and adolescent endocrinology — has been at the forefront of this shift.
For the women we see in the Denver metro and the San Luis Valley, that local academic leadership matters. The framework being adopted globally has been shaped, in part, by clinicians and researchers working right here. The standard of care that follows from this rename should reach patients in Colorado as fast as anywhere — and ideally faster, given the proximity.
The bottom line: PCOS is now PMOS, and the change is more than cosmetic. It reframes the condition as a multi-hormone, metabolism-first disorder — and treatment should follow. If you've been diagnosed and aren't sure your current plan reflects this newer understanding, it's worth a conversation.
Why We're Excited About This Change
Names matter. "Polycystic ovary syndrome" framed a complex endocrine and metabolic condition as a problem of ovarian cysts. That framing led to delayed diagnoses, fragmented treatment, and a lot of women being told they didn't have a condition that they obviously did.
"Polyendocrine metabolic ovarian syndrome" is a longer name. PMOS is harder to say than PCOS. But it's accurate, and accuracy matters more than convenience when we're talking about a condition that affects 170 million women globally and has real implications for fertility, cardiometabolic health, mental health, and quality of life.
The transition will take time. The Lancet article notes that full implementation across health systems is expected to take roughly three years. Insurance codes, clinical guidelines, patient education materials, electronic health record systems — all of these need to update. But the direction is set, and patients deserve to know that the framework is shifting.
If you have PMOS — or if you've been wondering whether you do, but haven't been able to get a clear answer from your provider — this is a good moment to take the conversation seriously. The medical community just collectively agreed that this condition deserves better than it's been getting. You should too.
Questions about PMOS care?
Our providers work with women navigating PMOS at every stage — from initial diagnosis to long-term metabolic and hormonal support. Schedule a consultation to discuss your situation.
Book a ConsultationThis blog post is for educational purposes only and does not constitute medical advice. PMOS (formerly PCOS) is a complex condition and treatment decisions should be made in consultation with a licensed medical provider familiar with your individual situation. GLP-1 receptor agonists referenced in this article are not FDA-approved for PMOS; their use for this indication is off-label. Individual results vary.